Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

... As Suppliers Shift Offerings

by Ann M. Thayer
December 8, 2008 | A version of this story appeared in Volume 86, Issue 49

Introgen Therapeutics is reorganizing to focus on its Houston-based manufacturing and service business, Introgen Technical Services. The firm has declared bankruptcy and will cut about 30 of its 45 employees. A few employees will continue to support regulatory filings for the company's anticancer therapy Advexin. Meanwhile, in the face of lower demand from small biotech firms, Wuxi PharmaTech says it will cease biologics manufacturing at its Philadelphia site, eliminating about 100 jobs, and instead devote the facility to biologics testing and cell services.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.